Sermorelin vs CJC-1295
A factual side-by-side from public databases — chemical identity, literature volume, and attributed independent-test coverage. Not a recommendation; we don't rank one above the other.
Sermorelin is discussed in the provided sources as a growth hormone secretagogue/growth hormone releasing hormone (GHRH) synthetic analog that is considered among compounds affecting GH/IGF-1 signaling pathways, and it also appears in research focused on doping detection and analytical stability/detection methods. (PMIDs: 41490200, 41966639, 34665524, 32257855, 37806509, 36787346)
CJC-1295 is described as a long-acting growth-hormone-releasing hormone (GHRH) analog. Clinical research in healthy adults reported sustained, dose-dependent increases in circulating growth hormone (GH) and insulin-like growth factor I (IGF-I) after subcutaneous administration, with effects persisting for days and no serious adverse reactions reported in the studied cohorts.
| Sermorelin | CJC-1295 | |
|---|---|---|
| Family | GHRH analogs | GHRH analogs |
| Research goals | GH axis support | GH axis support |
| Amino acids | — | — |
| Molecular formula | C149H246N44O42S | C165H269N47O46 |
| Molecular weight | 3357.9 g/mol | 3647.2 g/mol |
| CAS number | 86168-78-7 | 446262-90-4 |
| Approx. half-life | — | — |
| Regulatory status | Unknown | Unknown |
| WADA status | — | — |
| Evidence maturity | — | — |
| Research references | 8 | 8 |
| Vendors independently tested | 7 | 48 |
| Best test score (Finnrick) | 7.9 | 9.1 |